Cryo Cell International Inc
CCELNYSECIK 862692HealthcareFiscal year ends Nov 30
Reports and events: 256 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-1321:00 ET | DEF 14A | Proxy statementPeriod 2026-10-27 | 0001193125-26-420608 |
| 2026-10-0920:30 ET | 10-Q | Quarterly reportPeriod 2026-08-31 | 0001193125-26-419156 |
| 2026-09-1420:30 ET | 8-K | 8.01 Other events | 0001193125-26-390647 |
| 2026-07-1520:30 ET | 10-Q | Quarterly reportPeriod 2026-05-31 | 0001193125-26-304834 |
| 2026-07-0713:01 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001493152-26-032265 |
| 2026-05-0820:00 ET | 8-K | 3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-214569 |
| 2026-04-1421:00 ET | 10-Q | Quarterly reportPeriod 2026-02-28 | 0001193125-26-155057 |
| 2026-03-2501:54 ET | SCHEDULE 13D | Ownership report, active investor | 0001493152-26-012763 |
| 2026-03-1221:00 ET | 8-K | 3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-104392 |
| 2026-02-2722:01 ET | 10-K | Annual reportPeriod 2025-11-30 | 0001193125-26-083096 |
| 2025-11-1222:00 ET | 8-K | 8.01 Other events | 0001193125-25-277872 |
| 2025-10-2321:00 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-25-248883 |
| 2025-10-1521:00 ET | 10-Q | Quarterly reportPeriod 2025-08-31 | 0001193125-25-240385 |
| 2025-09-2621:00 ET | DEF 14A | Proxy statementPeriod 2025-10-21 | 0001193125-25-220757 |
| 2025-09-1021:00 ET | 8-K | 8.01 Other events | 0001193125-25-200170 |
| 2025-07-1521:00 ET | 10-Q | Quarterly reportPeriod 2025-05-31 | 0000950170-25-095916 |
| 2025-05-2221:00 ET | 8-K | 1.02 Termination of a material agreement | 0000950170-25-076433 |
| 2025-05-0821:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-067147 |
| 2025-04-1421:00 ET | 10-Q | Quarterly reportPeriod 2025-02-28 | 0000950170-25-053767 |
| 2025-02-2822:00 ET | 10-K | Annual reportPeriod 2024-11-30 | 0000950170-25-030138 |
| 2024-10-3121:15 ET | 8-K | 5.07 Shareholder vote results | 0000950170-24-119642 |
| 2024-10-3012:45 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-118607 |
| 2024-10-1721:13 ET | 10-Q/A | Quarterly report, amendedPeriod 2024-08-31 | 0000950170-24-115377 |
| 2024-10-1721:54 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-115106 |
| 2024-10-1521:18 ET | 10-Q | Quarterly reportPeriod 2024-08-31 | 0000950170-24-114762 |
| 2024-10-0721:00 ET | DEF 14A | Proxy statementPeriod 2024-10-29 | 0001193125-24-233861 |
| 2024-09-1721:00 ET | 8-K | 8.01 Other events | 0000950170-24-107340 |
| 2024-07-1521:00 ET | 10-Q | Quarterly reportPeriod 2024-05-31 | 0000950170-24-083637 |
| 2024-04-1521:10 ET | 10-Q | Quarterly reportPeriod 2024-02-29 | 0000950170-24-044493 |
| 2024-03-2612:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-036165 |
| 2024-02-2822:20 ET | 10-K | Annual reportPeriod 2023-11-30 | 0000950170-24-022275 |
| 2023-10-1221:01 ET | 10-Q | Quarterly reportPeriod 2023-08-31 | 0000950170-23-053143 |
| 2023-10-1220:30 ET | 8-K | 5.07 Shareholder vote results | 0000950170-23-053122 |
| 2023-09-1420:30 ET | DEF 14A | Proxy statementPeriod 2023-10-10 | 0001193125-23-235338 |
| 2023-08-2520:17 ET | 8-K | 8.01 Other events | 0001193125-23-221510 |
| 2023-07-1421:11 ET | 10-Q | Quarterly reportPeriod 2023-05-31 | 0000950170-23-033057 |
| 2023-04-2120:32 ET | 10-Q | Quarterly reportPeriod 2023-02-28 | 0000950170-23-013868 |
| 2023-03-0922:09 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-23-007079 |
| 2023-02-2822:29 ET | 10-K | Annual reportPeriod 2022-11-30 | 0000950170-23-005220 |
| 2022-12-2922:01 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-22-027095 |
| 2022-10-1800:31 ET | 10-Q | Quarterly reportPeriod 2022-08-31 | 0000950170-22-019626 |
| 2022-10-0521:00 ET | 8-K | 5.07 Shareholder vote results | 0000950170-22-019317 |
| 2022-09-1621:01 ET | DEF 14A | Proxy statementPeriod 2022-10-03 | 0001193125-22-246473 |
| 2022-08-2321:00 ET | 8-K | 8.01 Other events | 0000950170-22-017696 |
| 2022-08-2322:02 ET | 8-K | 8.01 Other events | 0000950170-22-017659 |
| 2022-07-2220:31 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0000950170-22-012926 |
| 2022-07-1121:01 ET | 10-Q | Quarterly reportPeriod 2022-05-31 | 0000950170-22-012605 |
| 2022-04-2800:37 ET | S-1/A | Registration statement, amended | 0001193125-22-124542 |
| 2022-04-2713:20 ET | 10-Q/A | Quarterly report, amendedPeriod 2022-02-28 | 0000950170-22-006286 |
| 2022-04-1320:31 ET | 10-Q | Quarterly reportPeriod 2022-02-28 | 0000950170-22-005662 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.